a 28-year-old Arab man
Class IV lupus nephritis from a rheumatoid arthritis and lupus overlap called Rhupus syndrome
He first took oral prednisolone, hydroxychloroquine, and mycophenolate mofetil, and improved. When he got worse and developed fluid around the lung (lupus pleuritis), his doctors gave him pulses of intravenous methylprednisolone and stronger oral treatment. He reached complete remission on a cyclosporine-based plan.
In this single case, a 28-year-old man with severe class IV lupus nephritis from Rhupus syndrome reached complete remission on a cyclosporine-based immune-suppressing plan after the first standard treatment failed.
- Lupus can attack the kidneys badly, and here a kidney biopsy confirmed the most active form, ISN/RPS class IV-G (A/C) diffuse lupus nephritis.
- The first plan of oral prednisolone, hydroxychloroquine, and mycophenolate mofetil helped at first, but the disease came back with fluid around the lung (lupus pleuritis).
- Doctors then escalated to intravenous methylprednisolone pulses and stronger oral treatment, and a cyclosporine-based plan was tied to complete remission.
- Rhupus, the overlap of rheumatoid arthritis and lupus, is uncommon, and the paper says the best immune-suppressing strategy for it is still poorly defined.
- The urine showed protein and microscopic blood, and the biopsy showed full-house immunofluorescence, both classic signs of lupus kidney disease.
Why it might work
In lupus nephritis the immune system attacks the person's own kidney tissue, which causes inflammation and leaking of protein and blood into the urine. The paper frames the treatment as turning down that overactive immune response with a series of immune-suppressing drugs. When the standard drugs were not enough, the team added a cyclosporine-based plan, and the disease was reported to go into complete remission. The paper does not spell out the exact mechanism, only that the right immune-suppressing strategy for this overlap disease is not well established.
The honest limits
- This is one patient (n=1), so it cannot tell us how often this plan works or who it works for.
- No eGFR, creatinine, or urine protein numbers are given, so the actual change in kidney function is not measured in the abstract.
- No timeframe is given for how long remission took or how long it lasted.
- The abstract shown does not disclose any conflicts of interest, so we cannot confirm whether the authors had any.
- Could an autoimmune disease like lupus be driving my kidney problem, and would a kidney biopsy help find out?
- If my current immune-suppressing medicine stops working, what stronger options, such as a calcineurin inhibitor like cyclosporine, might fit my case?
- Which lab numbers, like urine protein and kidney function, will we track to judge whether my treatment is working?